Wilkinson Global Asset Management LLC reduces its position in Johnson & Johnson (NYSE:JNJ)

0

Wilkinson Global Asset Management LLC reduced its stake in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) by 0.9% during the 1st quarter, according to the company in its latest filing with the Securities & Exchange Commission. The company held 22,166 shares of the company after selling 204 shares during the period. Wilkinson Global Asset Management LLC’s holdings in Johnson & Johnson were worth $3,929,000 when it last filed with the Securities & Exchange Commission.

Several other institutional investors also changed their stock holdings. Family CFO Inc purchased a new stake in Johnson & Johnson in Q4 worth approximately $26,000. Professional Financial Advisors LLC increased its stake in Johnson & Johnson by 47.9% in the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company valued at $37,000 after purchasing an additional 68 shares during the period. Joseph P. Lucia & Associates LLC purchased a new stake in Johnson & Johnson in Q1 worth approximately $38,000. Advocacy Wealth Management Services LLC increased its stake in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company valued at $41,000 after purchasing an additional 67 shares during the period. Finally, Gibson Wealth Advisors LLC acquired a new stake in Johnson & Johnson in Q4 valued at approximately $49,000. Hedge funds and other institutional investors own 68.78% of the company’s shares.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company in a trade that took place on Thursday, May 26. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a document filed with the SEC, which is available via this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company in a trade that took place on Thursday, May 26. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a document filed with the SEC, which is available via this link. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a trade that took place on Friday, June 10. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. The disclosure of this sale can be found here. 0.35% of the shares are currently held by company insiders.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $166.77 on Friday. The stock has a 50-day moving average price of $173.49 and a 200-day moving average price of $174.56. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt ratio of 0.37. The company has a market cap of $438.47 billion, a price-to-earnings ratio of 24.28, a growth price-to-earnings ratio of 3.19, and a beta of 0.59. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last reported quarterly results on Tuesday, July 19. The company reported earnings per share (EPS) of $2.59 for the quarter, beating analyst consensus estimates of $2.57 by $0.02. The company posted revenue of $24.02 billion in the quarter, versus a consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company’s quarterly revenue increased 3.0% from the same quarter last year. In the same period a year earlier, the company posted earnings per share of $2.48. Research analysts predict Johnson & Johnson will post EPS of 10.05 for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Investors of record on Tuesday, August 23 will receive a dividend of $1.13. This represents a dividend of $4.52 on an annualized basis and a yield of 2.71%. The ex-dividend date is Monday, August 22. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Changes to analyst ratings

Several analysts have recently released reports on the stock. Daiwa Capital Markets began covering Johnson & Johnson shares in a Wednesday, June 22 report. They issued an “outperformance” rating on the stock. Wells Fargo & Company raised its price target on Johnson & Johnson stock from $190.00 to $195.00 and gave the stock an “overweight” rating in a Wednesday, July 13 research note. UBS Group reduced its price target on Johnson & Johnson shares from $185.00 to $180.00 in a Thursday, July 21 research note. SVB Leerink reduced its price target on Johnson & Johnson shares from $200.00 to $194.00 in a Wednesday July 20 research note. Finally, Citigroup reduced its price target on Johnson & Johnson shares from $205.00 to $201.00 in a Wednesday, July 20 research note. Four investment analysts gave the stock a hold rating, five issued a buy rating and one gave the company’s stock a strong buy rating. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Profile

(Get an evaluation)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

See also

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Share.

Comments are closed.